EMPOWERING PHYSICIANS WITH EVIDENCE-BASED CONTENT
 

Home > Browse Topics

<< Sickle Cell Disease: A Comprehensive Review Of Inpatient Management

Treatment

Use of hydroxyurea in sickle cell anemia patients is one of the few instances where research has predominated in the adult instead of the pediatric group. Hydroxyurea treatment is indicated in patients with moderate to severe SCD (defined as 3 or more episodes of acute pain crises in a year) or an episode of acute chest syndrome within the last year. The cytotoxic effects of hydroxyurea exist via its inhibition of ribonucleotide reductase. Hydroxyurea has also been used for many years in myeloproliferative disorders (such as polycythemia vera). Because of a predilec tion for inhibition of rapidly dividing precursor cells, hydroxyurea decreases the production of HbS and indirectly increases the production of HbF.

To read the rest of this section, choose one of the options below.

Related Links:

EMplify, the new Emergency Medicine Practice podcast, is now available

 

About EB Medicine:

Products:

Accredited By:

ACCME ACCME
AMA AMA
ACEP ACEP
AAFP AAFP
AOA AOA
AAP AAP

Endorsed By:

AEMAA AEMAA
HONcode HONcode
STM STM

 

Last Modified: 07/23/2017
© EB Medicine